Problems for biomedical research at the academia-industrial interface
- Sir David Weatherall
- … show all 1 hide
Purchase on Springer.com
$39.95 / €34.95 / £29.95*
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.
Throughout much of the world, universities have driven towards industrial partnerships. This collaboration, which, in the biochemical field at least, has to continue if potential benefits for patients are to be realised, has brought with it a number of problems. These include the neglect of long-term research in favour of short-term projects, the curtailing of free dissemination of research information within university departments and the biasing of results of clinical trials by the financial interests of the investigators.
It is very important that governments, universities, and industry itself address these problems. Universities should monitor the amount of basic, curiosity-driven research that is being carried on, compared with that which is more short-term goal orientated. PhD students and post-doctoral fellows should be exposed to the principles of bioethics early on in their careers. Further work is necessary on the terms of research contracts to protect, on the one hand, the rights of individual scientists and, on the other, industry from rogue scientists. Where problems arise, procedures should be in place for independent reviews to be conducted by bodies such as the Medical Research Council in the UK or the National Institutes of Health in the USA. The conflict-of-interest rules recently introduced for publication in medical journals should be extended to all branches of science.
- Anon. (2001) Is the university-industrial complex out of control? Nature 409: 119.
- Olivieri, Nancy F. (2003) Patients’ health or company profits? The Toronto story, Science and Engineering Ethics 9: xx-xx.
- WHO (2002) Genomics and Global Health, WHO, Geneva.
- Comroe, J.H. and Dripps, R.D. (1977) The Top Ten Clinical Advances in Cardiovascular-Pulmonary Medicine and Surgery Between 1945 and 1975: How They Came About, 2 vols. U.S. Government Printing Office, Washington, D.C.
- Nadis, S. (2000) Med school to relax rules on business links? Nature, 403: 818. CrossRef
- Holden, C. (2000) NEJM admits breaking its own tough rules. Science: 287:1573. CrossRef
- Stelfox, H.T., Chua, G., O’Rourke, K. & Detsky, A.S. (1998) Conflict of interest in the debate over calcium-channel antagonists. New England Journal of Medicine 338: 101–106. CrossRef
- Friedberg, M. Saffran, B., Stinson, T.J., Nelson, W. & Bennett, C.L. (1999) Evaluation of conflict of interest in economic analyses of new drugs used in oncology. Journal of the American Medical Association 282: 1453–1457. CrossRef
- Eichenwald, K., Kolata, G. (1999) Research for hire. New York Times 16 March 1999.
- Carney, S.I., Nair, K.R., Sales, M.A. & Walsh, J. (2001) Pharmaceutical industry sponsored meetings: good value or just a free meal? Internal Medicine 31: 488–491. CrossRef
- Angell, M. (2000) Is academic medicine for sale? New England Journal of Medicine 342:1516–1518. CrossRef
- Smaglik, P. (2000) Gene therapy institute denies that errors led to trial death. Nature 403: 820. CrossRef
- Davidoff, F., DeAngelis, C.D., Drazen, J.M., et al (2001) Sponsorship, authorship and accountability, Lancet 358: 854–856. CrossRef
- Problems for biomedical research at the academia-industrial interface
Science and Engineering Ethics
Volume 9, Issue 1 , pp 43-48
- Cover Date
- Print ISSN
- Online ISSN
- Kluwer Academic Publishers
- Additional Links
- biomedical research
- conflict of interest
- commercialisation of science
- Author Affiliations
- 1. Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, OX3 9DS, Heddington, Oxford, United Kingdom